Skip to main content

2018 Technology in Psychiatry Summit: Closing Gaps in Translation

De-Risking Digital Development: Unpacking the Innovation Pipeline in Substance Use Disorder Treatment

Nov
1
2018

Date: November 1, 2018

Time: 2:35PM

Location: Boston, MA

The 2018 Technology in Psychiatry Summit will be held on November 1-2, 2018 at Harvard Medical School’s Joseph B. Martin Conference Center in Boston.

This year’s theme is “Closing Gaps in Translation,” both in the sense of using technology and pervasive sensing approaches to advance the detailed cross-species study of behavior in order to help bridge the human-nonhuman translational gap, as well as applying these approaches to improve mental health in under-resourced areas both globally and in the US (i.e., developing robust cross-cultural models of mental illness and culturally-tailored therapeutics).

With keynote addresses, panel discussions, and a poster session, attendees will examine the evolving state of global mental health efforts, cutting edge trends in neurosciences, and new technologies and analytical tools that are cross-cutting traditionally separate disciplines to help address some of the world’s most challenging problems.

De-Risking Digital Development: Unpacking the Innovation Pipeline in Substance Use Disorder Treatment

Despite the potential for “digital therapeutics” to transform the treatment landscape in behavioral health, the path through the digital development process is complex and evolving. From identifying a problem or need, to innovating a potential set of solutions, to finding the one that will scale effectively, to gaining regulatory approval, to creating a product or service, each of which is fraught with potential risk for those performing the work, but also for their funders and the pipeline for future treatments. In this session, our speakers will unpack each of these stages, focusing on the area of substance use.

After a brief introduction from (1) Dawn Sugarman, session will begin with prepared remarks from (2) David Epstein, (3) Lisa Marsch, (4) Bethany Hills, and (5) Dan Smith (~12-15 min). Then (5) David Barash reflects from podium on what was discussed as panelists take stage. Finally (6) other panelists join discussion, including curated set of questions that Dawn (or possibly David Barash) can paraphrase or pose directly to panelists.

Speakers

Aaron L. Josephson is a Senior Director of ML Strategies who advises clients on health care policy issues related to medical devices and pharmaceuticals. Earlier, he was with the US Food and Drug Administration, including as a senior policy advisor in the Center for Devices and Radiological Health.